Mayne Pharma is thrilled to announce a landmark funding raise of A$672,000,000, a significant milestone that will further accelerate our mission to offer patients better, safer, and more accessible medicines worldwide. As an ASX-listed specialty pharmaceutical company (ASX: MYX) with more than 40 years of innovation in developing oral drug delivery systems, this infusion of capital underscores market confidence in our robust business model and commitment to excellence in both novel and generic pharmaceuticals. Our track record of technological innovation and successful commercialization of products鈥攏ow represented by a global portfolio featuring over 90 marketed products鈥攔einforces our position as a global leader in the pharmaceutical industry.
This funding is strategically earmarked to expand our research and development initiatives, enhancing our pipeline of groundbreaking therapies. We plan to fuel the growth of both our commercial medicines and Mayne Contract Services, our full-service CDMO based in Salisbury, SA, which has been instrumental in serving clients worldwide. With a dedicated team of over 400 professionals and current annual revenues exceeding A$400m (FY22), this financial boost will enable us to capitalize on emerging opportunities, streamline operations, and invest in innovative drug delivery techniques that improve patient outcomes.
By reinforcing our corporate values of Empowerment, Passion, Creativity, Agility, Integrity, and Accountability, we are committed to delivering transformational healthcare solutions while driving sustainable growth. This milestone funding not only solidifies our market presence鈥攚ith a market cap exceeding A$500m鈥攂ut is also a testament to our unwavering dedication to advancing patient care on a global scale. To learn more about our journey and future plans, please visit www.maynepharma.com.
